The extracellular matrix transmits information to cells through interactions with membrane components, which directly activate many intracellular signaling events. Moreover, accumulating evidence suggests that eicosanoids derived from cyclooxygenase (COX)-2 participate in a number of pathological processes in immune-mediated renal diseases, and it is known that protein kinase B (AKT) may act through different transcription factors in the regulation of the COX-2 promoter. The present results show that progressive accumulation of collagen I in the extracellular medium induces a significant increase of COX-2 expression in human mesangial cells, resulting in an enhancement in PGE2 production. COX-2 overexpression is due to increased COX-2 mRNA levels. The study of the mechanism implicated in COX-2 upregulation by collagen I showed focal adhesion kinase (FAK) activation. Furthermore, we observed that the activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway by collagen I and collagen I-induced COX-2 overexpression was abolished by PI3K and AKT inhibitors. Additionally, we showed that the cAMP response element (CRE) transcription factor is implicated. Finally, we studied COX-2 expression in an animal model, N G -nitro-Larginine methyl ester hypertensive rats. In renal tissue and vascular walls, COX-2 and collagen type I content were upregulated. In summary, our results provide evidence that collagen type I increases COX-2 expression via the FAK/PI3K/AKT/cAMP response element binding protein signaling pathway.
ulus and afferent arteriole, whereas COX-2 is expressed constitutively in the cells of the macula densa (MD) and in scattered cells in the cortical thick ascending limb immediately adjacent to the MD and in a subset of medullary interstitial cells near the papillary tip in normal adult kidney (18, 19) . In the human kidney, COX-2 expression also has been reported to be present in podocytes, glomerular mesangial cells, and arteriolar smooth muscle cells (28) . COX-2 expression is also abundant in the lipid-laden medullary interstitial cells in the inner medulla and papilla (18, 19) . Some investigators have reported that COX-2 may also be expressed in inner medullary collecting duct cells or intercalated cells in the renal cortex (11) . Upregulation of the COX-2 isoform has been implicated in a wide variety of pathological processes, mainly those characterized by inflammation, suggesting that activation of COX-2 might play an important role in the pathogenesis and progression of nephropathies (6, 7) . Because inflammation and fibrosis are closely linked, there has also been an increasing interest in the effect of COX-2 on modulation of fibrotic changes in renal disease. Prostanoid production via COX is increased in various renal diseases (30, 33, 37, 48) and may serve to offset the profibrotic influence of factors such as transforming growth factor-␤ and angiotensin II, which may also be elevated in glomerular disease (35, 39) . Interestingly, evidence obtained in the past decade indicates that progression to advanced renal fibrosis requires the participation of inflammatory events such as COX-2 upregulation (21, 44) .
Renal fibrosis is the common final outcome of many clinical conditions, both inflammatory and noninflammatory, that lead to chronic renal failure (10) . It is characterized by a progressive substitution of cellular elements by extracellular matrix (ECM) proteins as a consequence of an imbalance in the rate of proliferation, necrosis, and apoptosis of the cells (20) , as well as the loss of the normal equilibrium between the synthesis and degradation of ECM (27, 50) . Glomerular mesangial cells seem to play a key role in the genesis of glomerular sclerosis (16) . Main components of the glomerular basement membrane and glomerular interstitium are collagens, proteoglycans, laminin, and nidogen (entactin) (22, 23) . In normal conditions, collagen IV seems to be the most relevant glomerular collagen, acting as an important anchorage substrate for many cell types, and the regulation of collagen IV synthesis and degradation plays an important role in cell function, growth, migration, and organ remodeling (18) . In pathological conditions, such as hypertension or diabetes, characterized by an augmented profibrotic cytokines at the local level (26, 41) , an increased ECM protein synthesis takes place at the glomerular level accompanied by qualitative changes in its composition (51, 52) . Thus, in some glomerular diseases, a progressive accumulation of interstitial collagen I (39) and a loss of basement membrane integrity, with decreased content of laminin and collagen IV, have been described (46) .
Changes in ECM composition may induce significant changes in cell phenotype. ECM proteins, through the interaction with transmembrane proteins that act as receptors (36) , may modify the growth pattern of the cells (29) , protect them from apoptosis (15) , induce changes in the synthesis of cellular autacoids (17, 34) , or modify the cellular content of proteins with well-defined biological activity (9) , with the subsequent changes in cell biology and organ structure and function.
As mentioned before, the relationship between COX-2 and renal fibrosis has only been studied to analyze the role of the enzyme in the protection against glomerular sclerosis (1) and tubulointerstitial scarring (42) or in the development of glomerular and tubulointerstitial injury (2) . However, the possibility that the very fibrosis may act as a regulatory mechanism of COX-2 expression has not been evaluated previously. Positive or negative feedback, regarding the enzyme expression, could be established in renal diseases with fibrosis, and this fact could have relevant consequences in the development of disease. In the present study, we hypothesized that changes in ECM composition could play a role in the regulation of COX-2 expression in human mesangial cells (HMC), and we devoted part of the experiments to analyze the mechanisms involved in this modulation.
EXPERIMENTAL PROCEDURES
Drugs and reagents, HMC culture, protein and RNA analysis Supplementary data for this article may be found on the American Journal of Physiology: Cell Physiology website.
Experimental design. Studies were performed in cells cultured on a thin film of collagen type I (COL I) or collagen type IV (COL IV). For this, culture plates were incubated for 16 h at 4°C in a solution of 12.5 g/ml COL I or COL IV in bicarbonate buffer [15 mM Na 2CO3 and 35 mM NaHCO3 (pH 9)] to allow the formation of a thin film of collagen, as described (24) . Next, the remaining collagen was discarded, and petri dishes were washed with Hanks' balanced salt solution to restore the pH. Trypsinized cells were seeded on the COL I-or COL IV-coated plates. Cells were grown for the indicated times in RPMI 1640 supplemented with 10% FBS. In the studies with soluble collagens, cells were grown to 90% confluency during 3 days, and they were treated with 12.5 g/ml COL I or COL IV. For inhibition experiments, cells were preincubated with the corresponding inhibitor for 1 h and continuously exposed to soluble COL I or COL IV plus the inhibitor.
Determination of PGE 2 formation. The cultured medium of HMC treated as described in the legends for Figs. 1-8 was collected and diluted two times. PGE2 concentrations in the medium were determined in triplicate using a commercially available enzyme immunoabsorbent assay kit (Cayman Chemical, Ann Arbor, MI) following the manufacturer's protocol. The assay was performed in a total volume of 150 l, with the following components being added in 50-l volumes: standards or biological samples, enzymatic tracer, and specific antiserum. After overnight incubation at 4°C, the plates were washed, and 200 l Ellman's reagent were added to each well. After 1-3 h, the absorbance at 414 nm of each well was measured. A standard curve, with values ranging from 50 to 0.39 pg/ml, was used to evaluate the concentrations. The reliable limit of quantification for PGE2 was 15 pg/ml, and the coefficient of variation was Ͻ14% within the calibration range (15-1,000 pg/ml). Results were calculated by using the nonlinear regression of a four-parameter logistic model. Each experiment was performed five times.
Transient transfection. Experiments Cells were plated in sixwell plates 24 h before transfection and incubated at 37°C until they were 60 -80% confluent. Next, cells were incubated for 8 h at 37°C with 2 ml Opti-MEM (Invitrogen) containing complexes of 5 g LipofectAMINE (Invitrogen), 1.0 g human COX-2 promoter luciferase construct reporter plasmids, and 0.1 g Renilla luciferase reporter as an internal control. Transfected cells were next incubated with complete growth medium for 16 h, and then they were serum-starved for 10 h before the cells were treated. Finally, firefly luciferase activity of the COX-2 reporter was measured with a Lumat LB9506 luminometer (Berthold Technologies, Herts, UK) and normalized against the Renilla luciferase activity by using the dual-luciferase reporter assay system (Promega, Madison, WI). Luciferase activity is represented as relative luciferase units of firefly per Renilla.
Small interfering RNA transfection. To deplete protein kinase B (AKT) protein with specific small interfering RNA (siRNA) oligonucleotides, experiments were performed as described (4) . Cells were seeded in six-well plates the day before transfection. Cells were incubated in 1 ml OPTIMEM with 100 nM Signal-Silencer AKT siRNA, which targets AKT1 and AKT2 (catalog no. 6211; Cell Signaling Technology, Beverly, MA), or Silencer negative control#1 siRNA (Ambion, Austin, TX), using LipofectAMINE. After 24 h incubation, 1 ml of medium containing FBS was added. Transfected cells were next incubated for 24 h, and then they were serum-starved for 10 h before the cells were treated, as reflected in the figure legends. Cells were harvested 24 h later.
Studies in animals. Twelve-week-old male Wistar rats were housed in a pathogen-free, temperature-controlled room (22 Ϯ 2°C). Food and water were available ad libitum. The rats were treated with N G -nitro-L-arginine methyl ester (L-NAME, 20 mg·kg Ϫ1 ·day Ϫ1 ) or water, and blood pressure was measured by a tail cuff sphygmomanometer (14) . After 4 wk, they were anesthetized with halothane, and kidneys and aortas were removed and shockfrozen immediately for Western blot analysis. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication no. 85-23, Revised 1996) and was supervised and approved by the veterinary authority of the animal facilities from Universidad de Alcala.
Data analysis and statistical procedures.
Results are reported as means Ϯ SE from at least three independent experiments, some performed in duplicate or triplicate. Statistical differences were tested by using nonparametric unpaired Mann-Whitney, Wilcoxon, or Friedman test, as needed. A P value Ͻ0.05 was considered significant.
RESULTS
Changes in COX-2 protein content and mRNA expression in HMC in contact with different collagen types. HMC grown on COL IV for up to 72 h exhibited a progressive decrease of COX-2 protein content (Fig. 1A ) similar to the one observed in plastic-cultured cells. In fact, COX-2 protein expression was similar in plastic-and COL IV-cultured cells at the different times tested (data not shown). The decrease in COX-2 was not observed in cells grown on COL I, and the levels of the protein were significantly higher than in the COL IV-grown cells. Differences were maximal at 72 h (Fig. 1A) . As a consequence of this difference, the synthesis of PGE 2 after 72 h on collagens was higher when the culture substrate was COL I (Fig. 1B) . No differences were observed in the protein content of COX-1 as a consequence of the culture substrate (results shown in Supplemental Fig. S1 ). Interestingly, the differences on COX-2 expression were also observed when different collagen proportions were used to plate the cells. As shown in Fig. 1C , COX-2 protein content increased when COL I proportion was augmented. The differences in COX-2 were also observed when plastic-plated cells were incubated with soluble collagens. COL IV did not modify the COX-2 protein content in HMC treated for 72 h, whereas COL I induced a significant increase of the protein that was maximal at 8 h, and remained for 48 h (Fig. 1D ). Similar effects were observed when cells grown in COL IV were incubated with soluble COL I (results shown in Supplemental Fig. S2) .
To analyze the mechanism involved in the changes in the protein content, the expression of COX-2 mRNA was examined in plastic-plated HMC treated for 24 h with both soluble collagen types. As shown in Fig. 2A , significant differences in the COX-2 mRNA expression were observed between both collagens. Furthermore, cells transiently transfected with P2-1900-LUC, a construct of the human COX-2 gene promoter linked to a reporter system, showed an increased luciferase activity when incubated with COL I, up to similar levels as cells treated with IL-1␤, a strong inducer of COX-2 (Fig. 2B) . No changes in the transcriptional activity of the promoter were observed in cells treated with soluble COL IV (Fig. 2B) . Thus the changes in the steady-state COX-2 mRNA levels seem to be the consequence of modifications in the transcriptional activity of its promoter.
COL I-dependent COX-2 upregulation is mediated by focal adhesion kinase and phosphatidylinositol 3-phosphate/AKT activation. HMC incubated with soluble COL I exhibited a rapid and sustained increase in focal adhesion kinase (FAK) β tyrosine 397 phosphorylation that was not observed in cells treated with COL IV (Fig. 3A) . Pretreatment of HMC with 10 M 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo3,4-dpyrimidine (PP2), a selective inhibitor of FAK activation, completely decreased COL I-induced COX-2 induction (Fig. 3B) . Similarly, significant differences were observed in AKT phosphorylation at Ser 473 when HMC were treated with both types of collagen. As shown in Fig. 4A , the treatment with COL I induced a sustained increase in the cellular content of the phosphorylated protein with respect to the COL IVtreated cells. The pharmacological blockade of phosphatidylinositol 3-kinase (PI3K) or AKT inhibited the COL I-induced upregulation of COX-2 protein content (Fig. 4B) , an effect that was also observed when cells were depleted from AKT with a specific siRNA (Fig. 4C) . The increased AKT phosphorylation induced by COL I was prevented by cell incubation with the inhibitor of FAK activation, PP2 (Fig. 4D) . Additionally, the possible involvement of the FAK/PI3K/AKT signaling pathway in the COL I-induced increase of COX-2 expression was analyzed by measuring the transcriptional activity of the COX-2 promoter in the presence of specific inhibitors. As shown in Fig. 5 , HMC pretreatment with the pharmacological antagonists of PI3K, AKT, or FAK inhibited the COL I-induced COX-2-increased promoter activity.
COL I-dependent COX-2 upregulation is mediated by the transcription factor cAMP response element-binding protein.
To identify the region in the COX-2 promoter responsible for COL I-mediated activation, HMC were transfected with different constructs of the human COX-2 promoter, linked to the luciferase reporter system. As shown Fig. 6A , progressive serial deletions of the promoter did not modify the COL I-induced promoter activity even in the shorter construct P2-192 containing the proximal phosphorylated nuclear factor of Fig. 3 . Role of focal adhesion kinase (FAK) in the changes in COX-2 expression induced by collagens. A: HMC were treated with soluble COL I (12.5 g/ml) and soluble COL IV (12.5 g/ml) for the indicated times, and FAK phosphorylation was assessed by Western blot (a representative blot is shown). Equal protein loading was confirmed by probing with anti-total FAK. The graphs present densitometric band analysis normalized to total FAK. The data represent means Ϯ SE of 5 independent experiments. *P Ͻ 0.01 vs. COL IV. B: effect of preincubation with the FAK inhibitor 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo3,4-dpyrimidine (PP2, 10 M, 1 h) on the COX-2 modulation induced by soluble collagens (12.5 g/ml, 24 h). Expression of COX-2 protein was analyzed by Western blot (a characteristic Western blot is shown). Equal protein loading was confirmed by probing with anti-␣-actin antibody. The graphs present densitometric band analysis normalized to ␣-actin. The data represent means Ϯ SE of 4 independent experiments. *P Ͻ 0.01 vs. COL IV. #P Ͻ 0.01 vs. COL I. activated T cells (NFAT) site and a cAMP response element (CRE) site of response to transcription factors. However, the specific mutation of this CRE site in the responsive p192 promoter (P2-192 CRE-MUT) completely abrogated the stimulatory effect of COL I. To further confirm the involvement of CRE transcription factor in COL I-induced COX-2 expression, we examined cAMP response element-binding protein (CREB) activation by analyzing its phosphorylation. An increased and sustained CREB phosphorylation on Ser 133 was detected in cells incubated with COL I, with respect to cells incubated with COL IV (Fig. 6B ). This CREB phosphorylation was prevented by addition of the FAK or AKT inhibitors to the cells (Fig. 6C) .
"In vivo" relationship between COL I and COX-2 tissue content.
To analyze the physiological relevance of the changes observed in cells, some studies were performed in hypertensive animals. Rats were treated for 4 wk with the NO synthase inhibitor L-NAME [blood pressure after 4 wk of L-NAME: 230 Ϯ 12 mmHg (P Ͻ 0.05); blood pressure in control rats: 142 Ϯ 10 mmHg], and the renal and vascular protein content of COL I and COX-2 was analyzed simultaneously. The results obtained are shown in Fig. 7, with Fig. 7A including the renal data and Fig. 7B the vascular data. In both cases, a significantly increased content of both proteins was observed. Moreover, these two parameters showed a highly significant statistical correlation.
DISCUSSION
Here, we demonstrated that COL I induces an increased expression of COX-2 in HMC with respect to plastic-or COL IV-cultured cells. This upregulation was observed not only when cells were cultured on COL I-covered plates but also when soluble COL I was added to cells cultured on plastic or COL IV. As a consequence of this overexpression, HMC cultured on COL I synthesized increased amounts of PGE 2 . The changes observed in the COX-2 protein content in HMC in contact with COL I seem to be the consequence of increased mRNA steady-state levels that were due, at least in part, to increased promoter activity. Similar results were previously published by Cho and colleagues (8) Simultaneous studies were performed in collagen-plated cells and in plastic-plated cells incubated with soluble collagens, and in both cases results were comparable. Studies in collagen-plated cells could better reproduce the pathophysiological conditions in damaged glomeruli, in which chronic changes in ECM composition would modify the expression of COX-2 in mesangial cells. However, to analyze the initial events that trigger COX-2 overexpression, studies in collagenplated cells could be inadequate. Immediately after plating, differences in adhesion or proliferation could exist, and the degree of confluence or the percentages of cells in the different phases of the cellular cycle could differ in both collagens. In these conditions, the changes observed could not be the consequence of the different collagen composition. Thus, after Fig. 4 . Role of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway in the changes in COX-2 expression induced by collagens. A: HMC were treated with soluble COL I (12.5 g/ml) and soluble COL IV (12.5 g/ml) for the indicated times, and AKT phosphorylation (P-AKT) was assessed by Western blot (a representative blot is shown). Equal protein loading was confirmed by probing with anti-total AKT. The graphs present densitometric band analysis normalized to total AKT. The data represent means Ϯ SE of 5 independent experiments. *P Ͻ 0.01 vs. COL IV. B: effect of preincubation with the PI3K inhibitor LY-294002 (20 M, 1 h) and AKT inhibitor (Inh, 30 M, 1 h) on the COX-2 modulation induced by soluble collagens (12.5 g/ml, 24 h). Expression of COX-2 protein was analyzed by Western blot (a characteristic Western blot is shown). Equal protein loading was confirmed by probing with anti-␣-actin antibody. The graphs present densitometric band analysis normalized to ␣-actin. The data represent means Ϯ SE of 4 independent experiments. *P Ͻ 0.01 vs. COL IV. #P Ͻ 0.01 vs. COL I. C: effect of AKT depletion on the COX-2 modulation induced by soluble collagens (12.5 g/ml, 24 h). Cells were depleted of AKT with a specific small-interfering RNA (siRNA), and a scrambled RNA (Sc) was used as control. Expression of COX-2 and AKT proteins was analyzed by Western blot (a characteristic Western blot is shown). Equal protein loading was confirmed by probing with anti-␣-actin antibody. The graphs present densitometric band analysis normalized to ␣-actin. The data represent means Ϯ SE of 3 independent experiments. *P Ͻ 0.01 vs. COL IV. #P Ͻ 0.01 vs. COL I. D: effect of preincubation with the FAK inhibitor PP2 (10 M, 1 h) on the AKT phosphorylation induced by soluble collagens (12.5 g/ml, 24 h). Equal protein loading was confirmed by probing with anti-total AKT antibody. The graphs present densitometric band analysis normalized to total AKT. The data represent means Ϯ SE of 4 independent experiments. *P Ͻ 0.01 vs. COL IV. #P Ͻ 0.01 vs. COL I. demonstrating that changes in COX-2 expression were similar in collagen-plated and collagen-incubated cells, we selected this later experimental approach to analyze the early cellular events that take place after collagen interaction.
The mechanisms involved in the COX-2 modulation by COL I were explored with a systematic approach that included 1) the measurement of the activity of proteins that are implied in the signal transmission of ECM protein stimuli to cells and 2) the consequences of the blockade of these proteins on COX-2 expression. FAK, PI3K, and AKT are some of the proteins activated after the interaction of collagen with transmembrane integrins (38, 43) . HMC treated with soluble COL I showed an increased phosphorylation of FAK and AKT, a fact that implies protein activation (31, 47) . The pharmacological blockade of the activity of the three proteins, as well as the cellular depletion of AKT with a siRNA, inhibited the COL I-dependent COX-2 upregulation, both at the protein level and in the promoter activity, supporting the relevance of these proteins in the COX-2 modulation under the proposed experimental conditions. Finally, to better establish the relationships between FAK and AKT, AKT phosphorylation was analyzed in the presence of FAK blockade. The results found suggest that FAK activation precedes the phosphorylation of AKT.
To gain further insight into the intracellular mechanisms that mediate the COL I-dependent COX-2 upregulation, cells were transfected with plasmids containing serial deletions of the COX-2 promoter (25) , and the luciferase activity was analyzed in the presence of both kinds of collagens. The results demonstrated that the transcription factors NF-B, NF-IL-6, and NFAT, involved in the modulation of the COX-2 promoter activity in some cell types (13, 32) , were not involved in the genesis of the differences between COL I and COL IV, since the deletion of their response elements in the promoter region did not modify these differences. Only the deletion of a fragment containing response elements to NFAT and CREB made changes in the luciferase activity after incubation with both collagens. The relevance of the CREB was supported by the fact that 1) phosphorylation of CREB increased in cells incubated with COL I, 2) this phosphorylation was abolished by FAK and AKT blockade, and 3) the directed mutation of the CREB response element in the COX-2 promoter region (25) completely abolished the luciferase changes induced by COL I.
Considering the data previously discussed, a possible putative model of COL I-induced COX-2 overexpression in HMC can be envisaged (Fig. 7) . Not every possible mechanism involved has been analyzed, and, thus, the possibility that alternative mechanisms could also be involved exists. In this regard, in intestinal epithelial cells, Broom and colleagues (3, 13) demonstrated that the coordinate activation of two transmembrane proteins, CD47 and ␣ 2 ␤ 1 -integrin, with the subsequent stimulation of PKC-␣, the small GTPase ras, and NF-B, seems to mediate the COX-2 upregulation induced by COL I. In contrast, Cho and colleagues (8) described that, for the same stimulus and effect but in a different cellular line, macrophages, FAK, PI3K, and CREB may be involved, but also p38 kinase, extracellular signal-regulated kinase 1/2, and CCAAT/ enhancer-binding protein.
A critical point concerning the present findings is the in vivo relevance of the observed effects in cells. The fact that variable mixtures of collagens modify the pattern of expression of COX-2 with a progressive increase as COL I proportion supports the importance of the findings. In fact, in pathophysiological conditions in vivo, cells are not expected to come in contact with just one collagen type but with different ECM proteins, both normal and abnormal. Interestingly, we found that, in animals with an increased COL I expression in kidney and vessel walls, such as hypertensive rats, the COX-2 expression parallels the changes in COL I tissue content, pointing to a possible relationship between these two phenomena. Further studies have to be carried out to definitively proof this relationship. The pathophysiological consequences of the increased COX-2 content when COL I is overexpressed have not been evaluated in our experiments. Specifically designed experiments in which the functional and structural consequences of the COX-2 blockade were analyzed, in a context characterized by COL I augmentation, ought to be performed. Previous reports have shown contradictory consequences of the administration of COX-2 inhibitors in renal diseases characterized by the accumulation of ECM. In some cases, the pharmacological blockade of COX-2 leads to a decrease in renal damage (5, 45) , whereas, in others, COX-2 overexpression is critical for the progression of the disease (5, 49) . Thus the modulation of the enzyme by COL I could be interpreted as a protective or a harmful mechanism. Careful experiments that analyze simultaneously the relationship between COL I and COX-2, and the consequences of the inhibition of the latter, must be performed to clarify the mechanisms of progression of renal damage in chronic renal diseases.
In summary, we reported here the first description of COX-2 upregulation by ECM proteins, particularly the proportion between COL I and COL IV, in HMC, and we describe part of the mechanisms involved in the development of this effect (Fig. 8) . Moreover, by analyzing an experimental model of hypertension characterized by an increased renal and vascular accumulation of COL I, we point to the possibility that this in vitro upregulation could also take place in vivo. Additional experiments are needed to better understand the pathophysiological consequences of these changes. 6 . Analysis of the transcription factors involved in the changes in COX-2 transcriptional activity induced by collagens. A: HMC were transiently transfected with human COX-2 promoter luciferase constructs P2-1900-LUC, P2-274-LUC, or P2-192-LUC or with the P2-192-LUC construct with the binding site for cAMP response element (CRE) mutated (P2-192 CRE-MUT) and pRL-TK-Renilla. Next, they were treated with soluble COL I (12.5 g/ml) or COL IV (12.5 g/ml) for 24 h and assayed for luciferase and Renilla activity. Luciferase activity was normalized with Renilla activity and concentration of proteins. The data represent means Ϯ SE of 4 independent experiments (triplicates) and are expressed as fold induction with respect to control values (untreated cells). *P Ͻ 0.01 vs. control and COL IV. B: HMC were treated with soluble COL I (12.5 g/ml) and soluble COL IV (12.5 g/ml) for the indicated times, and cAMP response element-binding protein (CREB) phosphorylation was assessed by Western blot (a representative blot is shown). Equal protein loading was confirmed by probing with anti-␣-actin. The graphs present densitometric band analysis normalized to ␣-actin. The data represent means Ϯ SE of 5 independent experiments. *P Ͻ 0.01 vs. COL IV. C: effect of preincubation with the FAK inhibitor PP2 (10 M, 1 h) and AKT inhibitor (30 M, 1 h) on the CREB phosphorylation induced by soluble collagens (12.5 g/ml, 24 h). Expression of CREB phosphorylation was assessed by Western blot (a representative blot is shown). Equal protein loading was confirmed by probing with anti-␣-actin antibody. The graphs present densitometric band analysis normalized to ␣-actin. The data represent means Ϯ SE of 4 independent experiments. C, control. *P Ͻ 0.01 vs. COL IV. #P Ͻ 0.01 vs. COL I. 
